Company news
Sangamo Therapeutics, Inc. news in 2021
Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
December 11, 2021
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
December 11, 2021
Sangamo Therapeutics Reports Recent Business and Clinical Highlights and Third Quarter 2021 Financial Results
November 3, 2021
Sangamo Therapeutics Announces Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Patients With Fabry Disease
November 3, 2021
Sangamo Therapeutics Announces Third Quarter 2021 Conference Call and Webcast
October 27, 2021
Sangamo Therapeutics Announces Participation at 2021 Wedbush PacGrow Healthcare Conference
August 8, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 4, 2021
Sangamo Therapeutics Announces Second Quarter 2021 Conference Call and Webcast
July 28, 2021
Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer
May 23, 2021
Sangamo Therapeutics Announces Participation at Jefferies Healthcare Conference
May 20, 2021
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
May 3, 2021
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
April 26, 2021
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
April 26, 2021
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
March 24, 2021
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
March 16, 2021
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
February 23, 2021
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
February 16, 2021
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
January 31, 2021
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
January 5, 2021
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021
Calls in 2021
Decks in 2021
- Technical Presentation (January 2021)
Technical · 16 slides · Jan 14, 2021